XCL1 and neoplasm: To determine whether LTN could enhance CAR-T cell activity against other tumor targets, we generated human-derived CD19-expressing MC38 and B16F10 cells (hCD19+MC38 and hCD19+B16F10) as alternative tumor targets of CAR-T therapy.